HOUSE OF REPRESENTATIVES

THE TWENTY-SECOND LEGISLATURE

REGULAR SESSION OF 2004

COMMITTEE ON HEALTH

Rep. Dennis A. Arakaki, Chair

Rep. Scott Y. Nishimoto, Vice Chair

Rep. Helene H. Hale

Rep. Corinne W.L. Ching

Rep. Michael Puamamo Kahikina

Rep. Lynn Finnegan

Rep. Maile S.L. Shimabukuro

Rep. Bud Stonebraker

COMMITTEE ON HUMAN SERVICES AND HOUSING

Rep. Michael Puamamo Kahikina, Chair

Rep. Maile S.L. Shimabukuro, Vice Chair

Rep. Dennis A. Arakaki

Rep. Corinne W.L. Ching

Rep. Helène H. Hale

Rep. Lynn Finnegan

Rep. Bertha C. Kawakami

Rep. Bud Stonebraker

Rep. Scott Y. Nishimoto

NOTICE OF INFORMATIONAL BRIEFING

DATE:

Thursday, April 8, 2004

TIME:

9:00 a.m. to 12:00 noon (break)

to reconvene at 1:00 p.m. to 3:30 p.m.

PLACE:

Auditorium

State Capitol

415 South Beretania Street

A G E N D A

     

The purpose of this Joint Informational Briefing is to discuss the prevention, education, intervention, and treatment of Crystal Methamphetamine (Crystal Meth or Ice). In addition, the panel will focus on community funding for programs dealing with Crystal Meth users and its effects on the person. The panel of speakers will consist of Nationally recognized experts on Crystal Meth and will also provide information on HB 2004, HD1, SD1 and SB3234, SD1.

The Hosts for this informational briefing are Rep. Arakaki, Rep. Michael P. Kahikina, and Allison Colker, Esq., National Conference of State Legislators.

Our Guest Speakers are:

Linda M. Rosen, M.D., Deputy Director, Department of Health, Health Resources Administration

DOH's Perspective on Hawaii's Ice Epidemic

Sherry Franklin, Director for Integrated Services, HMSA

Drug Prevention in the workplace

The Honorable Lieutenant Governor James "Duke" Aiona

Hawaii's Drug Control Strategy, Mission, and Goals

Darryl Inaba, Pharm. D., Haight Ashbury Free Clinics

Pharmacology of Crystal Meth and its Effect on the Addict, Current Policy on Crystal Meth and Treatment

Richard Rawson, Ph.D., UCLA Integrated Substance Abuse Programs; Principal Investigator

Methamphetamine Clinical Trials Group (UCLA/National Institute of Drug Abuse)

Extent of the Methamphetamine Epidemic and Elements of Successful Treatment for Methamphetamine Disorders

Andy Anderson, Director, CEO, Hina Mauka

Community Intervention and the Commercial Aspects of Treatment: Present Sources of Funding and Financial Obstacles to Treating the Addict

William Haning, M.D., Addiction Program Director (Psychiatry) and Associate Dean, University of Hawaii John A. Burns School of Medicine

Directions Provided by Research and Implications for Policy: The Public Health View of Methamphetamine Dependence

 

A LIGHT LUNCH WILL BE PROVIDED IN ROOM 329, BETWEEN 12 NOON TO 1:00 P.M., TO THE SPEAKERS, LEGISLATORS, PARTICIPANTS, AUDIENCE, LEGISLATIVE SUPPORT STAFF AND SARGENT AT ARMS SUPPORT STAFF. PLEASE NOTE, QUESTIONS AND ANSWERS ARE ENCOURAGED DURING THE LUNCH BREAK.

IF YOU REQUIRE SPECIAL ASSISTANCE OR AUXILIARY AIDS AND/OR SERVICES TO PARTICIPATE IN THE PUBLIC HEARING PROCESS OF THE STATE HOUSE (I.E., SIGN LANGUAGE INTERPRETER, WHEELCHAIR ACCESSIBILITY, OR PARKING DESIGNATED FOR THE DISABLED), PLEASE CONTACT THE COMMITTEE CLERK AT LEAST 24 HOURS PRIOR TO THE HEARING SO ARRANGEMENTS CAN BE MADE.

FOR FURTHER INFORMATION, PLEASE CALL THE COMMITTEE CLERK AT 586-6050.

 

________________________________________

Rep. Dennis A. Arakaki

Chair

________________________________________

Rep. Michael P. Kahikina

Chair